Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
I-80 Gold
IAUX
5
Barrick Mining
B
HK Stock MarketDetailed Quotes
09688 ZAI LAB
- 32.250
- -0.900-2.71%
15min DelayTrading Jun 16 10:32 CST
35.58BMarket Cap-18.15P/E (TTM)
33.600High31.950Low7.05MVolume33.300Open33.150Pre Close231.25MTurnover0.64%Turnover RatioLossP/E (Static)1.10BShares35.50052wk High5.64P/B35.58BFloat Cap12.32052wk Low--Dividend TTM1.10BShs Float151.200Historical High--Dividend LFY4.98%Amplitude10.560Historical Low32.818Avg Price100Lot Size--Div Yield TTM--Div Yield LFY
Market Insights
Popular Gold Mining Stocks Popular Gold Mining Stocks
Amidst the uncertain outlook of the trade war and escalating concerns about an economic recession, gold prices have repeatedly reached new highs this year, at one point surpassing $3,500 per ounce. This marks an almost 30% increase since the beginning of the year. For investors in U.S. equities, investing in gold mining stocks represents a significant opportunity to ride this wave. Amidst the uncertain outlook of the trade war and escalating concerns about an economic recession, gold prices have repeatedly reached new highs this year, at one point surpassing $3,500 per ounce. This marks an almost 30% increase since the beginning of the year. For investors in U.S. equities, investing in gold mining stocks represents a significant opportunity to ride this wave.
Unlock Now
ZAI LAB Stock Forum
Does anyone knows why Zai Lab suddenly pump so high?
Breakthrough: Zai Lab's Dual Cancer Therapies Show Promise in Resistant Tumors at AACR 2025
Breakthrough Lung Cancer Drug Data: New DLL3-Targeted ADC Trial Results Coming at ASCO 2025
First NTRK Cancer Treatment in China: NMPA Fast-Tracks Repotrectinib Review for Untreated Patient Market
China Accepts TIVDAK Application: 45% Lower Death Risk in Cervical Cancer Trial
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) has received Orphan Drug Designation (ODD) from the U.S. FDA for ZL-1310, their first-in-class DLL3 antibody-drug conjugate (ADC) designed to treat small cell lung cancer (SCLC). The designation comes after promising results from an ongoing Phase 1a/1b study in patients with previously treated extensive-stage SCL...
No comment yet